Prothena Corporation plc

NASDAQ:PRTA

Biotechnology

Healthcare
$8.35 +3.89%

+$0.33 today

Market cap
$428.77M
Beta
-0.32
P/E (TTM)
-3.1
EPS (TTM)
-$2.81
52W Low $5.64High $11.80

Volume 0.76M

Average 0.51M

PRTA Long-term Investments

Investments the company intends to hold for more than a year.

Prothena Corporation plcNASDAQ: PRTA

Long-term Investments · Q1 FY2026 · quarter ended Mar 2026

Long-term investments remains negative

Q1 FY2026 long-term investments was $860K, compared with $0 a year earlier.

Context

  • Long-term investments amounted to 0.2% of total assets at the end of Q1 FY2026, up 0.2 pp from a year earlier.
  • Long-term investments increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$860K+0.0% QoQ
Last fiscal yearDec 2025
$860K+0.0% YoY
Year agoMar 2025
$0— since
Long-term Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+0.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Long-term Investments history

USD · from the balance sheet

Latest · FY2025
860K USD
Year-over-year change
+0.0%

Long-term Investments vs competitors

How PRTA compares with its peers on the latest reported figures

  • Peers report in different currencies, so long-term investments is compared through growth and share of total assets rather than absolute size.
  • Long-term investments amounts to 0.2% of total assets for PRTA, versus a peer median of 0.0%.
PRTA Competitors
Long-term Investments for PRTA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
BIIBBiogen Inc.Jun 2026$831.8M USD+271.3%+2.1%2.6%
DNLIDenali Therapeutics Inc.Jun 2026$229.53M USD+192.5%+303.2%19.8%
PRTAProthena Corporation plcMar 2026$860K USD——0.2%
ACIUAC Immune S.A.Mar 2026CHF 585K CHF+0.0%—0.4%
ABOSAcumen Pharmaceuticals, Inc.Mar 2026$231K USD-99.5%—0.2%
ANNXAnnexon, Inc.Mar 2026$0 USD——0.0%
AVXLAnavex Life Sciences Corp.Dec 2025$0 USD——0.0%
NMRANeumora Therapeutics, Inc. Common StockMar 2026$0 USD——0.0%
CGTXCognition Therapeutics, Inc.Mar 2026$0 USD——0.0%
PMNProMIS Neurosciences, Inc.Jun 2026$0 USD——0.0%
Peer median (excluding PRTA) —+96.3%+152.6%0.0%

Competitors are the stored peer set for PRTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents579.09M710.41M618.83M471.39M307.53M
Short-term Investments00000
Net Receivables13K62K5.16M00
Inventory00000
Other Current Assets766K1.71M3.49M1.17M1.75M
Total Current Assets584.81M719.1M639.28M485.41M315.19M
Property, Plant & Equipment (Net)14.14M8.01M16M13.79M10.27M
Goodwill00000
Intangible Assets00000
Long-term Investments000860K860K
Tax Assets7.07M18.2M33.89M43.24M0
Other Non-current Assets3.35M12.73M7.21M3.81M482K
Total Non-current Assets24.56M38.94M57.1M61.7M11.61M
Total Assets609.37M758.04M696.38M547.11M326.8M
Account Payables3.69M9.27M25.39M7.77M5.88M
Short-term Debt00002.89M
Tax Payables00000
Deferred Revenue7.66M11.44M08.85M2.66M
Other Current Liabilities405K503K2.13M1.38M29.42M
Total Current Liabilities33.45M50.15M56.89M48.5M40.84M
Long-term Debt00005.49M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)102.93M85.29M67.41M3.45M0
Other Non-current Liabilities553K553K00(5.49M)
Total Non-current Liabilities109.87M85.85M78.13M11.68M5.49M
Total Liabilities143.32M135.99M135.02M60.18M46.33M
Common Stock466K521K537K538K538K
Retained Earnings(716.05M)(833M)(980.03M)(1.1B)(1.35B)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity466.04M622.04M561.37M486.93M280.47M
Total Debt12.33M6.47M11.84M10.84M13.86M
Net Debt(566.77M)(703.93M)(607M)(460.55M)(293.67M)

Prothena Corporation plc

NASDAQ:PRTA

Intrinsic Alpha fair value

Locked

Current Price

$8.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.